Abstract 5255
Background
PD-1/PD-L1 blockades have shown promising antitumor activity in clinical trials of advanced nasopharyngeal carcinoma (NPC). Being the most wildly used molecular imaging in clinic, 18F-FDG PET/CT provides multiple information of tumor biology. In this study, we investigated the association of PD-L1 expression with 18F-FDG uptake and clinical features in patients with NPC.
Methods
84 patients were initially histopathologically diagnosed with NPC between December 2016 and March 2019. All tissue specimens and PET/CT images were collected before any treatment. The PD-L1 antibody we used in this investigation was SP263 (Ventana, USA). High PD-L1 expression in tumor cells (TC) or tumor-infiltrating immune cells (TIIC) was defined as ≥ 50% of corresponding cells with membranous staining.
Results
The values of tumor SUVmax and TLG in patients with positive TC PD-L1 expression were significantly higher than those of negative TC PD-L1 expression (SUVmax: 10.3±4.1 vs. 6.9±3.2; P < 0.001; TLG: 77.7±64.5 vs. 35.0±20.5; P < 0.001), while the SUVmax values and TLG in patients with positive TIIC PD-L1 expression is lower than those of negative TIIC PD-L1 expression (SUVmax: 7.0±3.4 vs. 9.7±4.1; P = 0.011; TLG: 29.1±14.4 vs. 71.3±61.2; P = 0.001). Univariate analysis showed that the expression of PD-L1 in TC was associated with tumor T stage (P = 0.044) but not with serum Epstein-Barr virus (EBV) load (P = 0.816). On the other hand, the expression of PD-L1 in TIIC was related to both T stage (P = 0.028) and serum EBV load (P = 0.003). In multivariate logistic regression analysis, PD-L1 expression in TC was positively associated with tumor SUVmax (P = 0.003) and TLG (P = 0.001), while PD-L1 expression in TIIC was negatively associated with SUVmax (P = 0.038) and serum EBV load (P = 0.025). Through the ROC curve, the SUVmax cut-off value of 6.7 and the TLG cut-off value of 41.3 can be used to predict the PD-L1 status in TC with an accuracy of 78.6% and 71.4%, while the SUVmax cut-off value of 7.2 can be used to predict the PD-L1 status in TIIC with an accuracy of 72.6%.
Conclusions
18F-FDG uptake with NPC lesions were positively correlated with PD-L1 expression in TC and negatively correlated with PD-L1 expression in TIIC. 18F-FDG PET / CT imaging may be useful for predicting the PD-L1 status in patients with NPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract